Compare GRND & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRND | ARDX |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | GRND | ARDX |
|---|---|---|
| Price | $11.25 | $5.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $22.75 | $13.75 |
| AVG Volume (30 Days) | 1.7M | ★ 3.3M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $29.03 | $35.64 |
| Revenue Next Year | $21.87 | $34.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.79 | $3.50 |
| 52 Week High | $25.13 | $8.40 |
| Indicator | GRND | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 28.83 |
| Support Level | $9.79 | $5.47 |
| Resistance Level | $14.12 | $6.23 |
| Average True Range (ATR) | 0.52 | 0.35 |
| MACD | 0.18 | -0.22 |
| Stochastic Oscillator | 84.31 | 7.60 |
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.